Atosiban
Molecular formula:C43H67N11O12S2
Molecular weight: 994.19 g·mol−1
Patent period: —
Dositive specifications:–
Injection :–
Oral tablets: —
Injection: —
Biological Activity
Atosiban is a peptide Oxytocin Receptor Inhibitor. Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells and reduced influx of Ca2+ from the extracellular space through voltage-gated channels occur. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.
Chemical Properties
| Catalog Num | A14334 |
| CAS NO. | 90779-69-4 |
| FORMULA | C43H67N11O12S2 |
| M.WT | 994.2 |
| PURITY | _ |
| SMILES |
CC[C@H](C)[C@H]1C (=O)N[C@H](C(=O)N [C@H](C(=O)N[C@@H] (CSSCCC(=O)N[C@@H] (C(=O)N1)CC2=CC= C(C=C2)OCC)C(=O)N3 CCC[C@H]3C(=O)N [C@@H] (CCCN)C(=O)NCC(=O)N) CC(=O)N)[C@@H](C)O |
| STORAGE |
Store lyophilized at -20ºC , keep desiccated.In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. |
Online Inquiry
Cardiovascular Disease
Other Drug Peptide
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin- promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and related metabolic disorders.
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake.
Linaclotide is a potent and selective guanylate cyclase C agonist, developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.
